Inactive Instrument

TVAX BIOM Stock

Stocks

US87306M1099

Biotechnology & Medical Research

End-of-day quote
- USD - Intraday chart for TVAX BIOM
Manager TitleAgeSince
Chief Executive Officer - 2019-03-10
Chief Tech/Sci/R&D Officer 72 2011-07-13
Investor Relations Contact 70 -
Director TitleAgeSince
Chairman 84 2011-07-13
Director/Board Member 70 2011-07-13
Director/Board Member 62 2011-11-30
Change 5-day change 1-year change 3-year change Capi.($)
+5.04%+3.66%+50.62%+103.77% 70.24B
-0.58%-0.37%+35.20%+75.93% 62.63B
-3.18%-0.78%-14.14%+369.82% 27.36B
+0.16%-0.16%+26.73%+12.12% 25.71B
+2.20%-4.72%+2.19%-13.14% 24.83B
-0.85%-3.05%+17.99%-21.33% 19.52B
-7.03%-10.19%+161.91%+303.00% 15.51B
-3.91%-5.25%-9.16%+485.32% 14.66B
+4.96%+4.63%-2.75%+864.40% 14.69B
Average -0.36%-1.83%+29.84%+242.21% 30.57B
Weighted average by Cap. +0.65%-0.80%+31.99%+168.08%
Logo TVAX BIOM
TVAX Biomedical, Inc. is a clinical-stage development company advancing its targeted cell-based immunotherapy for the treatment of cancer. The Company offers immunotherapeutic cancer treatment platform for various types of cancers. The Company's lead candidate is TVI-Brain-1, which is used for the treatment of brain cancer and targets glioblastomas. The Company has completed Phase II trials for TVI-Brain-1. The Company's other candidate is TVI-Kidney-1, which is used for the treatment of kidney cancer and targets stage 4 renal cell carcinoma. The Company has completed Phase II trials for TVI-Kidney-1. The Company's immunotherapeutic cancer treatment platform, TVAX Immunotherapy, is a personalized combination of cancer cell vaccination and killer T cell treatment platform. The Company's subsidiary, TVAX Animal Health, is focused on adapting the TVAX Immunotherapy for applications in the veterinary sector with a focus on cancer in dogs.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!